Skip to main content Back to Top
Advertisement

6/1/2026

Midazolam Injection

Products Affected - Description

    • Midazolam injection, Avet Pharmaceuticals, 1 mg/mL, 2 mL vial, 25 count, NDC 23155-0600-41
    • Midazolam injection, Avet Pharmaceuticals, 5 mg/mL, 10 mL vial, 10 count, NDC 23155-0601-42
    • Midazolam injection, Avet Pharmaceuticals, 5 mg/mL, 5 mL vial, 10 count, NDC 23155-0601-41
    • Midazolam injection, Fresenius Kabi, 1 mg/mL, 2 mL RFID Smart Label prefilled syringe, 24 count, NDC 76045-0211-20
    • Midazolam injection, Fresenius Kabi, 1 mg/mL, 2 mL vial, 25 count, NDC 63323-0411-12
    • Midazolam injection, Hikma, 1 mg/mL, 2 mL prefilled syringe, 10 count, NDC 00641-6220-10
    • Midazolam injection, Hikma, 1 mg/mL, 2 mL vial, 25 count, NDC 00641-6057-25
    • Midazolam injection, Hikma, 1 mg/mL, 5 mL vial, 10 count, NDC 00641-6059-10
    • Midazolam injection, Hikma, 5 mg/mL, 1 mL vial, 25 count, NDC 00641-6061-25
    • Midazolam injection, Hikma, 5 mg/mL, 2 mL prefilled syringe, 10 count, NDC 00641-6219-10
    • Midazolam injection, Pfizer, 1 mg/mL, 2 mL preservative-free vial, 25 count, NDC 00409-0001-25
    • Midazolam injection, Pfizer, 1 mg/mL, 5 mL preservative-free vial, 10 count, NDC 00409-2305-05
    • Midazolam injection, Pfizer, 5 mg/mL, 1 mL preservative-free vial, 10 count, NDC 00409-2308-01
    • Midazolam injection, Pfizer, 5 mg/mL, 2 mL preservative-free vial, 10 count, NDC 00409-2308-02
    • Midazolam injection, Sagent, 1 mg/mL, 2 mL preservative-free vial, 10 count, NDC 25021-0655-02
    • Midazolam injection, Sagent, 1 mg/mL, 50 mL premixed bag, 10 count, NDC 25021-0688-82
    • Midazolam injection, Sagent, 5 mg/mL, 10 mL vial, 10 count, NDC 25021-0661-10
    • Midazolam injection, Somerset Therapeutics LLC, 1 mg/mL, 2 mL vial, 10 count, NDC 70069-0816-10
    • Midazolam injection, Somerset Therapeutics LLC, 1 mg/mL, 5 mL vial, 10 count, NDC 70069-0817-10

Reason for the Shortage

    • Akorn ceased operations in February 2023.
    • Avet hhas midazolam injection on shortage due to manufacturing delays.
    • Fresenius Kabi has midazolam injection on shortage due to increased demand and delayed shipping.
    • Hikma has midazolam injection on shortage due to increased demand.
    • Pfizer has midazolam injection on shortage due to manufacturing delays and increased demand.
    • Sagent did not provide a reason for the shortage.
    • Somerset did not provide a reason for the shortage.

Available Products

    • Midazolam injection, Fresenius Kabi, 1 mg/mL, 100 mL premixed bag, 10 count, NDC 65219-0650-10
    • Midazolam injection, Fresenius Kabi, 1 mg/mL, 5 mL vial, 25 count, NDC 63323-0411-25
    • Midazolam injection, Fresenius Kabi, 1 mg/mL, 50 mL premixed bag, 10 count, NDC 65219-0650-50
    • Midazolam injection, Fresenius Kabi, 5 mg/mL, 1 mL fill in 2 mL vial, 25 count, NDC 63323-0412-25
    • Midazolam injection, Fresenius Kabi, 5 mg/mL, 2 mL vial, 25 count, NDC 63323-0412-02
    • Midazolam injection, Hikma, 1 mg/mL, 10 mL vial, 10 count, NDC 00641-6056-10
    • Midazolam injection, Hikma, 1 mg/mL, 100 mL premixed bag, 10 count, NDC 00143-9380-10
    • Midazolam injection, Hikma, 1 mg/mL, 50 mL premixed bag, 10 count, NDC 00143-9379-10
    • Midazolam injection, Hikma, 5 mg/mL, 10 mL vial, 10 count, NDC 00641-6060-10
    • Midazolam injection, Hikma, 5 mg/mL, 2 mL vial, 25 count, NDC 00641-6063-25
    • Midazolam injection, Pfizer, 1 mg/mL, 10 mL vial, 10 count, NDC 00409-2587-05
    • Midazolam injection, Pfizer, 5 mg/mL, 10 mL vial, 10 count, NDC 00409-2596-05
    • Midazolam injection, Pfizer, 5 mg/mL, 5 mL vial, 10 count, NDC 00409-2596-03
    • Midazolam injection, Sagent, 1 mg/mL, 100 mL premixed bag, 10 count, NDC 25021-0688-87
    • Midazolam injection, WG Critical Care, 1 mg/mL, 100 mL premixed bag, 10 count, NDC 44567-0611-10
    • Midazolam injection, WG Critical Care, 1 mg/mL, 50 mL premixed bag, 10 count, NDC 44567-0610-10

Estimated Resupply Dates

    • Fresenius Kabi has midazolam 1 mg/mL 2 mL vials on back order and the company estimates a release date of early-June 2026. The 1 mg/mL 2 mL RFID Simplist syringes are on back order and the company cannot estimate a release date.
    • Hikma has midazolam 1 mg/mL 2 mL and 5 mL vials and 5 mg/mL 1 mL vials on back order and the company estimates a release date of mid-June 2026. The 1 mg/mL 2 mL prefilled syringes are on back order and the company estimates a release date of early- to mid-June 2026. The 5 mg/mL 2 mL prefilled syringes are on back order and the company cannot estimate a release date.
    • Pfizer has midazolam 1 mg/mL 2 mL and 5 mL vials and 5 mg/mL 1 mL and 2 mL vials available in limited supply with weekly releases.
    • Sagent has midazolam 1 mg/mL 2 mL vials and 5 mg/mL 10 mL vials on long-term back order and the company cannot estimate a release date. There are short-dated 1 mg/mL 50 mL premixed bags available with an expiration date of January 2027.
    • Somerset has midazolam 1 mg/mL 2 mL and 5 mL vials on long-term back order and the company cannot estimate a release date.

Updated

Updated June 1, 2026 by Michelle Wheeler, PharmD, Drug Information Specialist. Created June 25, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2026, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.
ADVERTISEMENT